Envista Holdings Co. (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVSTGet Free Report) have received an average recommendation of “Hold” from the fifteen brokerages that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $20.18.

A number of analysts recently weighed in on the stock. Mizuho assumed coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Morgan Stanley dropped their price objective on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Piper Sandler increased their price objective on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a report on Saturday, March 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th.

Get Our Latest Research Report on NVST

Envista Stock Up 2.3 %

Shares of NYSE:NVST opened at $16.63 on Friday. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -2.56, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista has a 1-year low of $15.15 and a 1-year high of $23.00. The company’s fifty day moving average is $19.99 and its two-hundred day moving average is $19.63. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVSTGet Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities analysts anticipate that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Huntington National Bank lifted its position in shares of Envista by 97.8% in the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Envista in the fourth quarter worth approximately $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Envista in the fourth quarter worth approximately $86,000.

Envista Company Profile

(Get Free Report

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

Recommended Stories

Analyst Recommendations for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.